• Respiri gives update on US market
  • Screening results from 19 of Emyria’s MDMA compounds have been returned
  • Telix reports strong half-year results

Respiratory disease specialist, Respiri (ASX:RSH), surged 14% this morning after updating the market of its US business.

The company said its wheezo RPM (remote patient monitoring) platform is gaining traction in the US, and is on track to close more major deals over the December 2022 quarter. Currently, Respiri has around 120+ qualified customer leads in its sale funnel.

One of the biggest clients to have signed on to date is the Michigan Children’s Hospital, where the wheezo platform is on track to go live in the September quarter. Michigan is part of a larger NYSE listed entity consisting of 60+ hospitals.

The wheezo system of breath sensor, app and cloud storage helps asthma sufferers and provides an easy way to keep track of wheeze every day, and log insights into possible triggers.

Patients using wheezo at home can keep a record of wheeze rates and a history, including self-reported symptoms, triggers and medication usage which is correlated with data like pollen and air quality.

Over time, they’re able to build a personal profile and can share a detailed history with their doctor.

Respire believes the US is an attractive market for wheezo as 50 million Americans are living with asthma and/or COPD (chronic obstructive pulmonary disease).

RPM monitoring is physician reimbursed in the US, with a projected market growing by CAGR 30%+ to US$85 billion by 2026.

Screening results of Emyria’s MDMA compounds

Emyria (ASX:EMD) and the University of Western Australia (UWA) have received positive screening results from the third batch of MDMA analogues sent to Eurofins.

All 19 compounds demonstrate no significant interactions with selected “anti-targets” (receptors and enzymes known to be involved in unwanted side effects).

A total of 125 compounds have now been successfully created and screened as part of Emyria’s unique “New Drug Discovery Program”, including 45 new MDMA analogues created since inception of the collaboration.

Emyria says multiple preclinical programs are underway to evaluate the potential of a select group of high priority compounds to become registered medicines.

Telix reports strong first half

Telix Pharma (ASX:TLX) has reported its first half results.

Revenue grew by 726% on pcp to $24 million, while bottom line shows a net loss of $70.9m compared to $32.5m loss in the previous corresponding half.

Telix says reimbursements of Illuccix in the US have driven sales growth significantly, and July saw a big jump in sales.

Illuccix is Telix’s radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

Telix believes PSMA imaging has the potential to shape patient-management treatments beyond just prostate cancer.

Looking ahead in the second half of FY22, Telix expects regulatory decisions for Illuccix in Europe, Canada, and Brazil.

A prostate and renal imaging bridging study will also commence in China in FY23.


Share prices today: